SMARCB1 and atypical teratoid rhabdoid tumor: SMARCB1-deficient tumors like atypical teratoid rhabdoid tumor (ATRT) are considered mutationally quiet; however, there have been a few isolated reports of using atezolizumab/pembrolizumab/nivolumab in this disease population with a minimal response [47].